Blood test could predict chemo response in breast cancer patients

NCT ID NCT07289282

Recruiting now Knowledge-focused Sponsor: Atlas University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at small molecules called microRNAs in the blood of 80 women with breast cancer. Researchers want to see if changes in these molecules can predict how well chemotherapy works before surgery. The goal is to find a simple blood test that helps doctors choose the best treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors personalize breast cancer treatment by using microRNA levels to predict which patients will respond well to chemotherapy before surgery.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly help participants. The findings may not lead to immediate changes in care, and the small size (80 people) limits how broadly the results can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER INVASIVE BREAST CARCINOMA MICRORNAS NEOADJUVANT THERAPY PATHOLOGICAL RESPONSE

Contacts and locations

Locations

Istanbul Atlas University Faculty of Medicine
RECRUITING

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.